Mergers & AcquisitionsMedium•16 November 2026•
1 min read
Eli Lilly to Acquire Calytrix Bio in Deal Valued at Up to $1.5 Billion
Key Facts
1Eli Lilly and Company has entered into a definitive agreement to acquire Calytrix Bio.
2Calytrix Bio focuses on developing precision therapies for myeloproliferative neoplasms.
Eli Lilly and Company's acquisition of Calytrix Bio is valued at up to $1.5 billion. The deal structure includes an upfront payment followed by subsequent payments tied to the achievement of specific clinical and regulatory milestones for myeloproliferative neoplasm therapies.
Eli Lilly (LLY) shares closed at $1443.5 on November 13, 2026. Benzinga reported that the acquisition is designed to strengthen the company's precision therapy capabilities for blood cancers and expand its long-term biotechnology pipeline.